Skip to content

Transparency. Performance. Growth.

Transparency. Performance. Growth.

NovaMed

Key financial highlights

Revenue (FY)

₦145.2bn

EBITDA Margin

18.4%

Capex (FY)

₦22.6bn

Export Markets

12

NovaMed

Annual reports

Annual Report 2025

2025

Annual Report 2024

2024

Annual Report 2023

2023

NovaMed

Financial statements

YearQ1Q2Q3Annual
2025PDFPDFPDFPDF
2024PDFPDFPDFPDF
2023PDFPDFPDFPDF

NovaMed

Corporate governance

NovaMed is committed to sound governance, independent oversight, and transparent reporting aligned with stakeholder expectations.

Corporate Governance

The Audit Committee supports oversight of financial reporting integrity, risk management, and compliance controls.

Stock information

NGX Listing (placeholder): NOVAMED

NOVAMED

Shareholder information

  • Dividends (policy overview)
  • AGM notices
  • Investor updates

Press releases

Press releases, industry updates, health tips, and events from NovaMed.

NovaMed

Investor relations contact

investors@novamedpharma.com

Send a message